Evaluating Insulin Delivery Systems Using Dynamic Glucose Region Plots and Risk Space Analysis
- PMID: 40807953
- PMCID: PMC12349224
- DOI: 10.3390/s25154788
Evaluating Insulin Delivery Systems Using Dynamic Glucose Region Plots and Risk Space Analysis
Abstract
Simultaneous values of glucose rate of change (RoC) and glucose can be presented in a dynamic glucose region plot, and risk spaces can be specified for (RoC, glucose) values expected to remain in the target range (glucose 3.9-10.0 mmol/L) or leave or return to the target range within the next 30 min. We downloaded continuous glucose monitoring (CGM) data for 60 days from persons with type 1 diabetes using two different systems for automated insulin delivery (AID), A (n = 65) or B (n = 85). The relative distribution of (RoC, glucose) values in risk spaces was compared. The fraction of all (RoC, glucose) values anticipated to remain in the target range in the next 30 min was higher with system A (62.5%) than with system B (56.8%) (difference 5.7, 95% CI (2.2-9.2%), p = 0.002). The fraction of (RoC, glucose) values in the target range with a risk of progressing to the above range (glucose > 10.0 mmol/L) was slightly lower in system A than in B (difference -1.1 (95% CI: -1.8--0.5%, p < 0.001). Dynamic glucose region plots and the concept of risk spaces are novel strategies to obtain insight into glucose homeostasis and to demonstrate clinically relevant differences comparing two AID systems.
Keywords: automated insulin delivery; continuous glucose monitoring; dynamic glucose region plots; glucose rate of change; risk space analysis; type 1 diabetes.
Conflict of interest statement
KWH has received research grants for an investigator-initiated study from Abbott Diabetes Care and Novo Nordisk.
Figures






Similar articles
-
Hybrid closed-loop systems for managing blood glucose levels in type 1 diabetes: a systematic review and economic modelling.Health Technol Assess. 2024 Dec;28(80):1-190. doi: 10.3310/JYPL3536. Health Technol Assess. 2024. PMID: 39673446 Free PMC article.
-
Continuous glucose monitoring systems for type 1 diabetes mellitus.Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2. Cochrane Database Syst Rev. 2012. PMID: 22258980 Free PMC article.
-
Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.Health Technol Assess. 2016 Feb;20(17):v-xxxi, 1-251. doi: 10.3310/hta20170. Health Technol Assess. 2016. PMID: 26933827 Free PMC article.
-
The interdependence of targets for continuous glucose monitoring outcomes in type 1 diabetes with automated insulin delivery.Diabetes Obes Metab. 2024 Dec;26(12):5836-5844. doi: 10.1111/dom.15955. Epub 2024 Sep 26. Diabetes Obes Metab. 2024. PMID: 39323365
-
Methods for insulin delivery and glucose monitoring in diabetes: summary of a comparative effectiveness review.J Manag Care Pharm. 2012 Aug;18(6 Suppl):S1-17. doi: 10.18553/jmcp.2012.18.s6-a.1. J Manag Care Pharm. 2012. PMID: 22984955 Free PMC article.
References
-
- Tornese G., Carletti C., Giangreco M., Nistico D., Faleschini E., Barbi E. Carbohydrate Tolerance Threshold for Unannounced Snacks in Children and Adolescents with Type 1 Diabetes Using an Advanced Hybrid Closed-Loop System. Diabetes Care. 2022;45:1486–1488. doi: 10.2337/dc21-2643. - DOI - PMC - PubMed
-
- Sherr J.L., Heinemann L., Fleming G.A., Bergenstal R.M., Bruttomesso D., Hanaire H., Holl R.W., Petrie J.R., Peters A.L., Evans M. Automated Insulin Delivery: Benefits, Challenges, and Recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetes Care. 2022;45:3058–3074. doi: 10.2337/dci22-0018. - DOI - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical